Literature DB >> 25747905

Interplay between receptor tyrosine kinases and hypoxia signaling in cancer.

Astrid A Glück1, Daniel M Aebersold1, Yitzhak Zimmer1, Michaela Medová2.   

Abstract

Deregulated signaling via receptor tyrosine kinase (RTK) pathways is prevalent in numerous types of human cancers and is commonly correlated with worst prognosis, resistance to various treatment modalities and increased mortality. Likewise, hypoxic tumors are often manifested by aggressive mode of growth and progression following an adaptive genetic reprogramming with consequent transcriptional activation of genes encoding proteins, which support tumor survival under low oxygen-related conditions. Consequently, both the hypoxia-inducible factor (HIF) system, which is the major mediator of hypoxia-related signaling, and numerous RTK systems are considered critical molecular targets in current cancer therapy. It is now evident that there is an intricate molecular crosstalk between RTKs and hypoxia-related signaling in the sense that hypoxia can activate expression of particular RTKs and/or their corresponding ligands, while some RTK systems have been shown to trigger activation of the HIF machinery. Moreover, signaling regulation of some RTK systems under hypoxic conditions has also been documented to take place in a HIF-independent manner. With this review we aim at overviewing the most current observations on that topic and highlight the importance of the potential co-drugging the HIF system along with particular relevant RTKs for better tumor growth control.
Copyright © 2015 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Cancer; HIF system; Hypoxia; RTKs; VEGF

Mesh:

Substances:

Year:  2015        PMID: 25747905     DOI: 10.1016/j.biocel.2015.02.018

Source DB:  PubMed          Journal:  Int J Biochem Cell Biol        ISSN: 1357-2725            Impact factor:   5.085


  13 in total

Review 1.  Recent Advances on the Role of G Protein-Coupled Receptors in Hypoxia-Mediated Signaling.

Authors:  Rosamaria Lappano; Damiano Rigiracciolo; Paola De Marco; Silvia Avino; Anna Rita Cappello; Camillo Rosano; Marcello Maggiolini; Ernestina Marianna De Francesco
Journal:  AAPS J       Date:  2016-02-10       Impact factor: 4.009

Review 2.  The role of hypoxic signalling in metastasis: towards translating knowledge of basic biology into novel anti-tumour strategies.

Authors:  Joaquín Araos; Jonathan P Sleeman; Boyan K Garvalov
Journal:  Clin Exp Metastasis       Date:  2018-08-31       Impact factor: 5.150

3.  Identification of a MET-eIF4G1 translational regulation axis that controls HIF-1α levels under hypoxia.

Authors:  Astrid A Glück; Eleonora Orlando; Dominic Leiser; Michaela Poliaková; Lluís Nisa; Aurélie Quintin; Jacopo Gavini; Deborah M Stroka; Sabina Berezowska; Lukas Bubendorf; Andree Blaukat; Daniel M Aebersold; Michaela Medová; Yitzhak Zimmer
Journal:  Oncogene       Date:  2018-05-02       Impact factor: 9.867

Review 4.  Role of miRNAs in hypoxia-related disorders.

Authors:  A Gupta; R Sugadev; Y K Sharma; Y Yahmad; P Khurana
Journal:  J Biosci       Date:  2018-09       Impact factor: 1.826

Review 5.  Progress toward overcoming hypoxia-induced resistance to solid tumor therapy.

Authors:  Sergey V Karakashev; Mauricio J Reginato
Journal:  Cancer Manag Res       Date:  2015-08-12       Impact factor: 3.989

6.  Characterizing the Hot Spots Involved in RON-MSPβ Complex Formation Using In Silico Alanine Scanning Mutagenesis and Molecular Dynamics Simulation.

Authors:  Omid Zarei; Maryam Hamzeh-Mivehroud; Silvia Benvenuti; Fulya Ustun-Alkan; Siavoush Dastmalchi
Journal:  Adv Pharm Bull       Date:  2017-04-13

7.  Uncoupling protein 2 downregulation by hypoxia through repression of peroxisome proliferator-activated receptor γ promotes chemoresistance of non-small cell lung cancer.

Authors:  Mingxing Wang; Guoyin Li; Zhiwei Yang; Lei Wang; Lei Zhang; Ting Wang; Yimeng Zhang; Shengli Zhang; Yong Han; Lintao Jia
Journal:  Oncotarget       Date:  2017-01-31

8.  Encircling the regions of the pharmacogenomic landscape that determine drug response.

Authors:  Adrià Fernández-Torras; Miquel Duran-Frigola; Patrick Aloy
Journal:  Genome Med       Date:  2019-03-26       Impact factor: 15.266

9.  Impact of MET targeting on tumor-associated angiogenesis and growth of MET mutations-driven models of liver cancer.

Authors:  Anne-Christine Piguet; Michaela Medová; Adrian Keogh; Astrid A Glück; Daniel M Aebersold; Jean-François Dufour; Yitzhak Zimmer
Journal:  Genes Cancer       Date:  2015-07

Review 10.  Targeting the hypoxic fraction of tumours using hypoxia-activated prodrugs.

Authors:  Roger M Phillips
Journal:  Cancer Chemother Pharmacol       Date:  2016-01-25       Impact factor: 3.333

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.